Data confirm elevated inflammatory biomarkers in newborns with Hypoxic Ischemic Encephalopathy (HIE) and demonstrate a predictable pharmacokinetic profile for RLS-0071...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreNORFOLK, Va.–ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the...
Read MoreNORFOLK, Va. – February 25, 2025 – ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated...
Read More